KRK Krka, d. d.

GPW · PL · Healthcare · Drug Manufacturers - Specialty & Generic · krka.biz

1108.00PLN-1.25%Mkt Cap: 8.50B $P/E: 18.423d ago

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Centr…

Industry Peers

Drug Manufacturers - Specialty & Generic

Screen all

MRK

MERCK Kommanditgesellschaft auf Aktien

$64.70BUSDP/E 25.1

TAK

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

$57.06BUSD

TEVA

Teva Pharmaceutical Industries Limited Ordinary Shares

$46.10BUSDP/E 65.9

HLN

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

$38.70BUSDP/E 18.3

ZTS

Zoetis Inc. Class A Common Stock

United Therapeutics Corporation - Common Stock

$23.23BUSDP/E 19.4

VTRS

Viatris Inc. - Common Stock

$20.22BUSD

SOBI

Swedish Orphan Biovitrum AB

$14.24BUSDP/E 109.4

NBIX

Neurocrine Biosciences, Inc. - Common Stock

Elanco Animal Health Incorporated Common Stock

$11.06BUSD

RDY

Dr. Reddy's Laboratories Ltd Common Stock

$10.20BUSDP/E 29.2

AMRX

Amneal Pharmaceuticals, Inc. - Class A Common Stock

$7.07BUSDP/E 42.3

ALKS

Alkermes plc - Ordinary Shares

$7.00BUSDP/E 109.9

HIMS

Hims & Hers Health, Inc. Class A Common Stock

$6.77BUSD

LNTH

Lantheus Holdings, Inc. - Common Stock

$6.53BUSDP/E 23.9

KNSA

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

$5.83BUSDP/E 76.6

HIK

Hikma Pharmaceuticals PLC

$4.19BUSDP/E 11.9

INDV

Indivior Pharmaceuticals, Inc. - Common Stock

$4.21BUSDP/E 12.8

Key Statistics

Company

Market Cap8.50B USD

Enterprise Value8.43B USD

Revenue (TTM)534.84M USD

Gross Profit299.61M USD

Net Income (TTM)102.12M USD

Revenue/Share69.51 PLN

Last Price1108.00 PLN

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees13.3K

CountryPL

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISINSI0031102120

Valuation

P/E (Trailing)18.42

P/E (Forward)—

PEG—

EV/EBITDA54.93

EV/Revenue15.76

P/S16.09

P/B13.02

EPS (TTM)60.09

EPS (Forward)—

52W Range

748.0080% of range1200.00

52W High1200.00 PLN

52W Low748.00 PLN

Profitability

Gross Margin57.96%

Oper. Margin28.47%

EBITDA Margin28.69%

Profit Margin19.76%

ROE17.10%

ROA13.25%

Growth

Revenue Growth5.20%

Earnings Growth63.30%

Cash Flow & Leverage

Operating CF133.88M USD

CapEx (TTM)24.91M USD

FCF Margin8.48%

FCF Yield0.53%

Net Debt-179.61M USD

Net Debt/EBITDA-1.17

Balance Sheet

Debt/Equity0.01

Current Ratio4.21

Quick Ratio2.79

Book Value/Sh86.19 PLN

Cash/Share24.03 PLN

Dividends

Fwd Div Rate39.40 PLN

Trail. Div Rate9.10 PLN

Div. Yield3.47%

5Y Avg Yield4.92%

Payout Ratio59.96%

Ex-Div DateJul 21, 2026

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.30.28M

Float21.00M

Insiders16.33%

Institutions13.14%

Technical

SMA 501131.16 (-2.0%)

SMA 2001048.91 (+5.6%)

Beta0.43

S&P 52W Chg13.94%

Avg Vol (30d)70

Avg Vol (10d)27

Technical Indicators

RSI (14)39.7

MACD-2.1755

MACD Signal0.1414

MACD Hist.-2.3168

BB Upper1146.66 PLN

BB Middle1130.90 PLN

BB Lower1115.14 PLN

BB Width2.79%

ATR (14)17.73 PLN

Vol Ratio (20d)1.72x